A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin

Gynecologic Oncology
Mansoor Raza MirzaKamma Bertelsen

Abstract

Treatment of epithelial ovarian cancer patients relapsing with a short treatment-free interval (TFI) after prior chemotherapy is unsatisfactory. This phase II trial evaluated the activity and feasibility of pegylated liposomal doxorubicin (PLD) plus gemcitabine in this setting. Patients who had received prior platinum and paclitaxel with a TFI 0-12 months received PLD 25 mg/m(2)day 1 plus gemcitabine 800 mg/m(2)day 1, 8 every 21 days. Gemcitabine was dose escalated to 1000 mg/m(2)day 1, 8 from course 2 in the absence of grade 3/4 toxicity. The primary endpoint was progression-free survival (PFS). Patients were stratified according to response to primary chemotherapy. Seventy-nine patients (n=26 with CR on prior chemotherapy and TFI 6-12 months; n=20 with CR and TFI 0-6 months; n=33 with PR/SD and TFI 0-12 months) were enrolled. The median age was 59 years (range 31-77 years), and 33 patients had received ≥ 2 prior treatments. A median of five courses was delivered per patient (total 389 courses). Gemcitabine was dose escalated in 124 courses and reduced in 105 courses. No PLD dose reductions occurred. Grade 3/4 toxicities were febrile neutropenia (n=4), PPE (n=2), and mucositis (n=2). One toxic death occurred (pneumonitis/alveo...Continue Reading

References

Jan 17, 1996·Journal of the National Cancer Institute·S TretliP Vaittinen
Nov 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A L ThomasK J O'Byrne
Dec 6, 2000·Journal of Computer Assisted Tomography·P M BoiselleM S Huberman
Jun 26, 2001·British Journal of Clinical Pharmacology·N StallardA Whitehead
Aug 8, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·E Pujade-LauraineJ P Lotz
Jul 11, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G AravantinosM A Dimopoulos
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas J Herzog
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacobus PfistererUNKNOWN EORTC GCG
Feb 17, 2007·Expert Opinion on Investigational Drugs·Domenica LorussoGiovanni Scambia
Oct 17, 2007·Current Oncology·M Fung-Kee-FungP Bryson
Mar 16, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J E KurtzUNKNOWN Gynecologic Cancer Intergroup

❮ Previous
Next ❯

Citations

Jul 8, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J SehouliA González-Martín
Nov 3, 2011·Current Oncology Reports·Marcia Hall, Gordon Rustin
Feb 14, 2015·Taiwanese Journal of Obstetrics & Gynecology·Jui-Chun ChangChien-Hsing Lu
Aug 10, 2013·Journal of Experimental & Clinical Cancer Research : CR·Patrizia ViciLuigi Di Lauro
May 31, 2016·Journal of the Egyptian National Cancer Institute·Mohamed Elshebeiny, Walid Almorsy
Apr 22, 2014·Molecular and Cellular Endocrinology·Marta LlauradóMarina Rigau
Dec 14, 2011·Expert Review of Anticancer Therapy·Joseph A RakowskiRobert W Holloway
Mar 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J SehouliA González-Martín

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
J S TanguayI Fernando
Annals of Oncology : Official Journal of the European Society for Medical Oncology
P M L H VenckenC Seynaeve
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Annamaria FerreroPaolo Zola
© 2021 Meta ULC. All rights reserved